Ian Mortimer Sells 40,000 Shares of Xenon Pharmaceuticals (NASDAQ:XENE) Stock

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) CEO Ian Mortimer sold 40,000 shares of the stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $44.43, for a total value of $1,777,200.00. Following the sale, the chief executive officer directly owned 6,000 shares in the company, valued at $266,580. This represents a 86.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Ian Mortimer also recently made the following trade(s):

• On Monday, December 8th, Ian Mortimer sold 10,830 shares of Xenon Pharmaceuticals stock. The shares were sold at an average price of $45.73, for a total value of $495,255.90.
• On Friday, December 5th, Ian Mortimer sold 14,375 shares of Xenon Pharmaceuticals stock. The stock was sold at an average price of $45.03, for a total value of $647,306.25.
• On Friday, November 28th, Ian Mortimer sold 97 shares of Xenon Pharmaceuticals stock. The stock was sold at an average price of $45.01, for a total value of $4,365.97.

Xenon Pharmaceuticals Stock Down 0.7%

Shares of NASDAQ XENE traded down $0.33 during midday trading on Friday, reaching $44.49. 1,166,387 shares of the stock were exchanged, compared to its average volume of 708,094. The firm has a market cap of $3.44 billion, a price-to-earnings ratio of -11.44 and a beta of 0.97. The firm has a 50-day simple moving average of $42.59 and a two-hundred day simple moving average of $38.21. Xenon Pharmaceuticals Inc. has a twelve month low of $26.74 and a twelve month high of $46.60.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its earnings results on Monday, November 3rd. The biopharmaceutical company reported ($1.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.16) by $0.01. During the same quarter last year, the firm earned ($0.81) earnings per share. The business’s revenue was up .0% compared to the same quarter last year. Research analysts expect that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently issued reports on XENE. Needham & Company LLC reissued a “buy” rating and set a $55.00 target price on shares of Xenon Pharmaceuticals in a research note on Tuesday, November 4th. William Blair reaffirmed an “outperform” rating on shares of Xenon Pharmaceuticals in a report on Tuesday, October 7th. Royal Bank Of Canada increased their price target on Xenon Pharmaceuticals from $55.00 to $58.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 4th. JPMorgan Chase & Co. boosted their price objective on Xenon Pharmaceuticals from $57.00 to $60.00 and gave the company an “overweight” rating in a research report on Tuesday, November 18th. Finally, Chardan Capital raised shares of Xenon Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, November 19th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $54.64.

Institutional Investors Weigh In On Xenon Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. Farther Finance Advisors LLC purchased a new position in shares of Xenon Pharmaceuticals in the second quarter worth about $25,000. Danske Bank A S acquired a new stake in Xenon Pharmaceuticals in the 3rd quarter valued at about $32,000. Aster Capital Management DIFC Ltd acquired a new stake in Xenon Pharmaceuticals in the 3rd quarter valued at about $39,000. Elevation Point Wealth Partners LLC purchased a new position in Xenon Pharmaceuticals in the 2nd quarter worth approximately $32,000. Finally, State of Wyoming lifted its stake in Xenon Pharmaceuticals by 112.8% in the 3rd quarter. State of Wyoming now owns 1,151 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 610 shares in the last quarter. 95.45% of the stock is currently owned by institutional investors and hedge funds.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.